Iodine Radioisotopes

• 

  Subject Areas on Research

  • 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. 
  • 125I embedded in an orbital prosthesis for retreatment of recurrent retinoblastoma. 
  • 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. 
  • 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. 
  • 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. 
  • 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. 
  • A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. 
  • A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. 
  • A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. 
  • A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB). 
  • A procedure for the preferential radioiodination of small amounts of protein in the presence of excess lipids. 
  • A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells. 
  • Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy. 
  • Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. 
  • Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein. 
  • Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. 
  • Adenosine triphosphate activates ion permeabilities in biliary epithelial cells. 
  • Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. 
  • Alterations in receptors for sensory neuropeptides in human inflammatory bowel disease. 
  • Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. 
  • An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine. 
  • Angiotensinogen synthesis in the liver is independent of physiological estrogen levels. 
  • Antidepressant effects of nicotine in an animal model of depression. 
  • Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. 
  • Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer. 
  • Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma. 
  • Association between ankyrin and the cytoplasmic domain of band 3 isolated from the human erythrocyte membrane. 
  • Association between human erythrocyte calmodulin and the cytoplasmic surface of human erythrocyte membranes. 
  • Association of brain ankyrin with brain membranes and isolation of active proteolytic fragments of membrane-associated ankyrin-binding protein(s). 
  • Autodegradation of 125I-labeled human epidermal cell surface proteins. 
  • Binding of [125I]-N-(p-aminophenethyl)spiroperidol to the D-2 dopamine receptor in the neurointermediate lobe of the rat pituitary gland: a thermodynamic study. 
  • Binding of native and reduced and carbamidomethylated hGH to rabbit liver plasma membranes. 
  • Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants. 
  • Biological activity of oxidized and reduced iodinated bombesins. 
  • Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer. 
  • Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds. 
  • Bombesin receptors on gastrin cells. 
  • Bombesin/GRP-preferring and neuromedin B-preferring receptors in the rat urogenital system. 
  • Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ. 
  • Brain cholecystokinin receptors. Binding characteristics, covalent cross-linking, and evolutionary aspects. 
  • Brain phantom: high-resolution imaging with SPECT and I-123. 
  • CCK-A- and CCK-B-like receptors in the gallbladder and stomach of the alligator (Alligator mississippiensis). 
  • Captopril renography in the diagnosis of renovascular disease. 
  • Carbohydrate recognition systems in amphibians: primitive alpha 2-macroglobulin receptors. 
  • Carcinoid tumors: iodine-131 MIBG scintigraphy. 
  • Cardiac cryosurgery: regional myocardial blood flow of ventricular cryolesions. 
  • Carrier-free 131I-meta-iodobenzylguanidine: comparison of production from meta-diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine. 
  • Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. 
  • Catabolism of streptokinase and polyethylene glycol-streptokinase: evidence for transport of intact forms through the biliary system in the mouse. 
  • Cellular uptake and processing of surfactant lipids and apoprotein SP-A by rat lung. 
  • Characterization of a rat type 2 angiotensin II receptor stably expressed in 293 cells. 
  • Characterization of angiotensin II-receptor subtypes in podocytes. 
  • Characterization of antibodies to the rat substance P (NK-1) receptor and to a chimeric substance P receptor expressed in mammalian cells. 
  • Characterization of liposomes containing iodine-125-labeled radiographic contrast agents. 
  • Characterization of peptide YY receptors in rabbit colonic mucosa. 
  • Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. 
  • Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. 
  • Cholecystokinin and neuropeptide Y receptors on single rabbit vagal afferent ganglion neurons: site of prejunctional modulation of visceral sensory neurons. 
  • Cholera toxin and cell growth: role of membrane gangliosides. 
  • Circulating IgA immune complexes in patients with psoriasis. 
  • Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. 
  • Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. 
  • Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein. 
  • Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. 
  • Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment. 
  • Comparison of [125I]HIPDm and [125I]iodoantipyrine in quantifying regional cerebral blood flow in rats. 
  • Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. 
  • Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. 
  • Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. 
  • Comparison of various methods for delivering radiolabeled monoclonal antibody to normal rat brain. 
  • Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. 
  • Covalent labeling of the beta-adrenergic ligand-binding site with para-(bromoacetamidyl)benzylcarazolol. A highly potent beta-adrenergic affinity label. 
  • Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells. 
  • D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. 
  • Design, synthesis, and functional assessment of Cmpd-15 derivatives as negative allosteric modulators for the β2-adrenergic receptor. 
  • Detection of oncornavirus antigenic activity in human urothelial tissues. 
  • Development and characterization of a monoclonal antibody to human embryonal carcinoma. 
  • Development of a fluorescent ligand-binding assay using the AcroWell filter plate. 
  • Development of a radioimmunoassay for fetal antigen 2. 
  • Developmental regulation of insulin-like growth factor binding protein production: studies in fetal, postnatal, and pregnant sheep. 
  • Diagnostic accuracy and pitfalls of [iodine-131]6-beta-iodomethyl-19-norcholesterol (NP-59) imaging. 
  • Differential localization of cholecystokinin-8 binding sites in the rat vs. the guinea pig brain. 
  • Differential solubilization of placental lactogen (PL)- and growth hormone-binding sites: further evidence for a unique PL receptor in fetal and maternal liver. 
  • Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. 
  • Domains of the parathyroid hormone (PTH) receptor required for regulation by G protein-coupled receptor kinases (GRKs). 
  • Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? 
  • Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. 
  • Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. 
  • Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. 
  • Down regulation of macrophage mannose/N-acetylglucosamine receptors by elevated glucose concentrations. 
  • Early macular morphological changes following plaque radiotherapy for uveal melanoma. 
  • Editorial comment. 
  • Effect of fibronectin amount and conformation on the strength of endothelial cell adhesion to HEMA/EMA copolymers. 
  • Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. 
  • Effects of characteristic x-rays on assay of I-123 by dose calibrator. 
  • Effects of fetal dexamethasone exposure on postnatal control of cardiac adenylate cyclase: beta-adrenergic receptor coupling to Gs regulatory protein. 
  • Effects of insulin-like growth factors I and II and insulin on the immortalized hypothalamic GTI-7 cell line. 
  • Effects of specific activity on meta-[(131)I]iodobenzylguanidine kinetics in isolated rat heart. 
  • Efficacy and Safety of Low-Dose Iodine Plaque Brachytherapy for Juxtapapillary Choroidal Melanoma. 
  • Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. 
  • Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. 
  • Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. 
  • Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation. 
  • Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia. 
  • Enzyme occupancy measurement of intracellular protein tyrosine phosphatase 1B using photoaffinity probes. 
  • Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer. 
  • Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. 
  • Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. 
  • Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. 
  • Fabrication and testing of a device capable of reducing the incidence of ventricular shunt promoted metastasis. 
  • Ferromagnetic hyperthermia and iodine 125 brachytherapy in the treatment of choroidal melanoma in a rabbit model. 
  • First reported case of unilateral Graves' disease in the left lobe of a bilobar thyroid gland. 
  • First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. 
  • Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. 
  • Future alternatives to heparin: low-molecular-weight heparin and hirudin. 
  • Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. 
  • Growth factor receptors as molecular targets for cancer diagnosis and therapy. 
  • Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody. 
  • Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. 
  • Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. 
  • Hepatocyte uptake of alpha 1-proteinase inhibitor-trypsin complexes in vitro: evidence for a shared uptake mechanism for proteinase complexes of alpha 1-proteinase inhibitor and antithrombin III. 
  • Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. 
  • Human melanoma and leukemia associated antigens difined by nonhuman primate antisera. 
  • Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. 
  • Humoral immunostimulation. IV. Role of complement. 
  • Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. 
  • I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer. 
  • Identification of the ligand-binding subunit of the human 5-hydroxytryptamine1A receptor with N-(p-azido-m-[125I] iodophenethyl)spiperone, a high affinity radioiodinated photoaffinity probe. 
  • Imaging thyroid disease: updates, imaging approach, and management pearls. 
  • Immunodiagnosis of tumors in vivo using radiolabeled monoclonal antibody A2B5. 
  • Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. 
  • Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. 
  • In regards to Wallner et al: (125)I versus (103)PD for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial (Int J Radiat Oncol Biol Phys 2003;57:1297-1303). 
  • In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. 
  • In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. 
  • In vivo imaging of brain nicotinic acetylcholine receptors with 5-[123I]iodo-A-85380 using single photon emission computed tomography. 
  • In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies. 
  • In vivo lysis of L5178Y cells in the establishment of the tumor-dormant state in DBA/2 mice. 
  • In vivo studies with [125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. 
  • In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody. 
  • Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions. 
  • Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. 
  • Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. 
  • Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. 
  • Insular thyroid cancer: a population-level analysis of patient characteristics and predictors of survival. 
  • Interaction sites of the C-terminal region of the cGMP phosphodiesterase inhibitory subunit with the GDP-bound transducin alpha-subunit. 
  • Interaction sites of the COOH-terminal region of the gamma subunit of cGMP phosphodiesterase with the GTP-bound alpha subunit of transducin. 
  • Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. 
  • Intravitreal triamcinolone acetonide for acute radiation papillopathy. 
  • Iodine 131-labeled metaiodobenzylguanidine scintigraphy and biochemical analyses in suspected pheochromocytoma. 
  • Iodine-123-4-amino-3-iodobenzylguanidine, a new sympathoadrenal imaging agent: comparison with iodine-123 metaiodobenzylguanidine. 
  • Iodine-125 interstitial irradiation of virally induced dog brain tumours. 
  • Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. 
  • Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. 
  • Iodine-131-metaiodobenzylguanidine uptake in metastatic carcinoid tumor to the orbit. 
  • Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. 
  • Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer. 
  • Labeling monoclonal antibodies with halogen nuclides. 
  • Labeling proteins using aryl iodide acylation agents: influence of meta vs para substitution on in vivo stability. 
  • Large scale purification of factor X by hydrophobic chromatography. 
  • Localization and characterization of pancreatic polypeptide receptors in rat adrenal glands. 
  • Localization of I-131-labeled goat and primate anti-carcinoembryonic antigen(CEA) antibodies in patients with cancer. 
  • Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures. 
  • Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. 
  • Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. 
  • Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). 
  • Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. 
  • Loss of autoreceptor functions in mice lacking the dopamine transporter. 
  • Lymphovascular invasion is associated with survival for papillary thyroid cancer. 
  • Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma. 
  • Measurement of endothelial permeability to 125I-low density lipoproteins in rabbit arteries by use of en face preparations. 
  • Mechanism of action of cholera toxin and the mobile receptor theory of hormone receptor-adenylate cyclase interactions. 
  • Mechanisms of desensitization and resensitization of G protein-coupled neurokinin1 and neurokinin2 receptors. 
  • Members of the G protein-coupled receptor kinase family that phosphorylate the beta2-adrenergic receptor facilitate sequestration. 
  • Membrane receptors as general markers for plasma membrane isolation procedures. The use of 125-I-labeled wheat germ agglutinin, insulin, and cholera toxin. 
  • Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. 
  • Meta-iodobenzylguanidine and analogues: chemistry and biology. 
  • Meta-iodobenzylguanidine derivatives containing a second guanidine moiety. 
  • Metabolic behavior of C3 in normal, C4-deficient (C4D) and cortisone-treated guinea pigs. 
  • Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. 
  • Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate. 
  • Mineral metabolites and CKD progression in African Americans. 
  • Minimally invasive follicular carcinoma: predictors of vascular invasion and impact on patterns of care. 
  • Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery. 
  • Modulation of thyroidal radioiodine uptake by theophylline. 
  • Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine. 
  • Monitor peptide binding sites are expressed in the rat liver and small intestine. 
  • Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments. 
  • Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. 
  • Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. 
  • Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. 
  • N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. 
  • N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. 
  • N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. 
  • N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination. 
  • Nearest neighbor analysis for brain synapsin I. Evidence from in vitro reassociation assays for association with membrane protein(s) and the Mr = 68,000 neurofilament subunit. 
  • Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies. 
  • Neuroendocrine effects of dehydration in mice lacking the angiotensin AT1a receptor. 
  • Neurofilament phosphorylation and [125I]calmodulin binding by Ca2+/calmodulin-dependent protein kinase in the brain subcellular fractions of diisopropyl phosphorofluoridate (DFP)-treated hen. 
  • Neuropeptide Y/peptide YY receptor binding sites in the heart: localization and pharmacological characterization. 
  • New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment. 
  • New therapeutic options in the management of childhood brain tumors. 
  • Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. 
  • No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine. 
  • No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. 
  • No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation. 
  • No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue. 
  • No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. 
  • Norepinephrine-induced down regulation of alpha 1 adrenergic receptors in cultured rabbit aorta smooth muscle cells. 
  • Nutritional regulation of the placental lactogen receptor in fetal liver: implications for fetal metabolism and growth. 
  • O6-3-[125I]iodobenzyl-2'-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT). 
  • O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase. 
  • On the feasibility of polyurethane based 3D dosimeters with optical CT for dosimetric verification of low energy photon brachytherapy seeds. 
  • Oncornavirus-like protein expression in human prostatic tissue. 
  • Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. 
  • Organ distribution of Corynebacterium parvum labeled with iodine-125. 
  • Overexpression of beta-arrestin and beta-adrenergic receptor kinase augment desensitization of beta 2-adrenergic receptors. 
  • PDGF-stimulated fibroblast proliferation is enhanced synergistically by receptor-recognized alpha 2-macroglobulin. 
  • Patterns of use and cost for inappropriate radioactive iodine treatment for thyroid cancer in the United States: use and misuse. 
  • Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma. 
  • Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. 
  • Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. 
  • Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. 
  • Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. 
  • Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. 
  • Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. 
  • Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. 
  • Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. 
  • Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. 
  • Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane. 
  • Photoaffinity cross-linking of a radioiodinated probe, 125I-A55453, into alpha 1-adrenergic receptors. 
  • Photoaffinity labeling of mammalian alpha 1-adrenergic receptors. Identification of the ligand binding subunit with a high affinity radioiodinated probe. 
  • Photoaffinity labeling of the D2-dopamine receptor using a novel high affinity radioiodinated probe. 
  • Polyethylene glycol modification of serpins improves therapeutic potential. 
  • Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. 
  • Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. 
  • Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide. 
  • Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. 
  • Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide. 
  • Preparation of 5-[131I]iodo- and 5-[211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil by a halodestannylation reaction. 
  • Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteins. 
  • Prolonged exercise alters beta-adrenergic responsiveness in healthy sedentary humans. 
  • Prostate brachytherapy: a descriptive analysis from CaPSURE. 
  • Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents. 
  • Quantitative SPECT reconstruction of iodine-123 data. 
  • Quantitative imaging of iodine-131 distributions in brain tumors with pinhole SPECT: a phantom study. 
  • Radioactive Iodine Treatment Is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma. 
  • Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. 
  • Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate. 
  • Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. 
  • Radioimmunotherapy for Non-Hodgkin's Lymphoma. 
  • Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. 
  • Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. 
  • Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. 
  • Radioiodinated O(6)-Benzylguanine derivatives containing an azido function. 
  • Radioiodinated antibody targeting of the HER-2/neu oncoprotein. 
  • Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. 
  • Radioiodination and astatination of octreotide by conjugation labeling. 
  • Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate. 
  • Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. 
  • Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. 
  • Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate. 
  • Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. 
  • Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers. 
  • Radiolabeled antibodies, albumin and antimony sulfide colloid: a comparison as lymphoscintigraphic agents. 
  • Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate. 
  • Radiosynthesis and preliminary evaluation of 5-[123/125I]iodo-3-(2(S)-azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors. 
  • Rapid measurements of diastolic intramyocardial vascular volume. 
  • Re: Dosimetric consequences of increased seed strength for I-125 prostate implants. Radiother Oncol. 2003 Sep;68(3):295-7. 
  • Receptor binding sites for atrial natriuretic factor are expressed by brown adipose tissue. 
  • Receptors for sensory neuropeptides in human inflammatory diseases: implications for the effector role of sensory neurons. 
  • Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. 
  • Regarding "A moment with endocrinology and metabolism" Maryland Medical Journal November 1993. 
  • Regional pulmonary distribution of iodine-125-labeled oleic acid. Its relationship to the pattern of oleic acid edema and pulmonary blood flow. 
  • Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. 
  • Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). 
  • Reticuloendothelial clearance of radiolabelled pneumococci in experimental bacteremia: correlation of changes in clearance rates, sequestration patterns, and opsonization requirements at different phases of the bacterial growth cycle. 
  • SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies. 
  • SPECT/CT localization of oral radioiodine activity: a retrospective study and in-vitro assessment. 
  • Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. 
  • Secretin receptors mediating rat forestomach relaxation. 
  • Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. 
  • Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells. 
  • Solutions to problems in dose calibrator assay of iodine-123. 
  • Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. 
  • Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs). 
  • Specificity, cross-reactivity, and affinity of 125I-labeled antiglioma antibodies for monolayers of cultured glioma cells. 
  • Stability of the beta-adrenergic receptor/adenylyl cyclase pathway of pediatric myocardium after brain death. 
  • Studying regional brain function: a challenge for SPECT. 
  • Substance P and substance K receptor binding sites in the human gastrointestinal tract: localization by autoradiography. 
  • Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein. 
  • Sulfhydryl-reactive, cleavable, and radioiodinatable benzophenone photoprobes for study of protein-protein interaction. 
  • Surgical management of strabismus following choroidal melanoma plaque brachytherapy. 
  • Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. 
  • Synthesis and biological evaluation of an 123I-labeled bicyclic nucleoside analogue (BCNA) as potential SPECT tracer for VZV-tk reporter gene imaging. 
  • Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor. 
  • Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. 
  • Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability. 
  • Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. 
  • Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma. 
  • Synthesis of iodine-125 labeled (+/-)-15-(4-azidobenzyl)carazolol: a potent beta-adrenergic photoaffinity probe. 
  • Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling. 
  • Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates. 
  • Targeting aldehyde dehydrogenase: a potential approach for cell labeling. 
  • Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. 
  • Testing of local gamma-ray scatter fractions determined by spectral fitting. 
  • Thallium-201 uptake in lung cancer. 
  • The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. 
  • The Impact of Pathologically Positive Lymph Nodes in the Clinically Negative Neck: An Analysis of 39,301 Patients with Papillary Thyroid Cancer. 
  • The binding of fucose-containing glycoproteins by hepatic lectins. Re-examination of the clearance from blood and the binding to membrane receptors and pure lectins. 
  • The cardiac beta-adrenergic receptor. Structural similarities of beta 1 and beta 2 receptor subtypes demonstrated by photoaffinity labeling. 
  • The clearance of a monoclonal anti-DNA antibody following administration of DNA in normal and autoimmune mice. 
  • The clearance of glycoproteins in diabetic mice. 
  • The distribution of intimal white blood cells in the normal rabbit aorta. 
  • The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. 
  • The in vivo metabolism of antithrombin III and antithrombin III complexes. 
  • The rat testicular A1 adenosine receptor-adenylate cyclase system. 
  • The role of complement in the localization of pneumococci in the splanchnic reticuloendothelial system during experimental bacteremia. 
  • The role of fine needle aspiration in the management of the thyroid nodule. 
  • Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. 
  • Thyroid cancer in childhood: a retrospective review of childhood course. 
  • Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. 
  • Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. 
  • Transfer of radioiodine from iodinated oncornavirus proteins to unlabeled protein carrier during routine procedures for peptide mapping. 
  • Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6. 
  • Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions. 
  • Truncated forms of the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor encompassing the IGF-II binding site: characterization of a point mutation that abolishes IGF-II binding. 
  • Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. 
  • Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. 
  • Use of radiolabeled monoclonal anti-B1 antibody for B lymphocyte imaging in rhesus monkeys. 
  • Use of the 125I-labeled protein gel overlay technique to study calmodulin-binding proteins. 
  • Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. 
  • Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. 
  • Variables associated with postoperative deep venous thrombosis: a prospective study of 411 gynecology patients and creation of a prognostic model. 
  • Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. 
  • Vasoactive intestinal peptide (VIP) receptors in the canine gastrointestinal tract. 
  • Volume and activity quantitation with iodine-123 SPECT. 
  • Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma. 
  • Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. 
  • d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution. 
• 

  Keywords of People

  • Bennett, Vann, George B. Geller Professor for Research in Molecular Biology in the School of Medicine, Duke Cancer Institute
  • Buckley, Anne Frances, Assistant Professor of Pathology, Pathology
  • Freemark, Michael Scott, Robert C. Atkins, M.D. and Veronica Atkins Professor of Pediatrics, in the School of Medicine, Pediatrics, Endocrinology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Reiman Jr., Robert Ellis, Associate Professor of Radiology, Radiology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Schwartz-Bloom, Rochelle D., Professor in Pharmacology & Cancer Biology, Duke Science & Society
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology